Insights
Search Results
Client Highlights
8.04.25
Firm Advises Prime Medicine on IP Matters Related to $144 Million Public Offering
On August 1, 2025, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.
Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the offering. The Wilson Sonsini team included Lou Lieto, Clark Lin, Rachna Ujwal, and Esther Cynn.
Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the offering. The Wilson Sonsini team included Lou Lieto, Clark Lin, Rachna Ujwal, and Esther Cynn.
Client Highlights
5.12.25
Firm Advises HAYA Therapeutics on Patent Matters Related to $65 Million Series A Financing
On May 8, 2025, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 million in Series A funding. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly, ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors. Wilson Sonsini Goodrich & Rosati advised HAYA Therapeutics on patent matters related to the transaction.
Client Highlights
9.05.24
Wilson Sonsini Advises HAYA Therapeutics on Patent Matters Related to Collaboration with Eli Lilly
On September 4, 2024, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. Wilson Sonsini Goodrich & Rosati advised HAYA on patent matters related to the transaction.
Client Highlights
2.22.24
Wilson Sonsini Advises Prime Medicine on IP Matters Related to Upsized Public Offering
On February 20, 2024, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock. Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction.
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
Client Highlights
9.28.23
Wilson Sonsini Advises Adela on Patent Matters Related to $48 Million Financing
On September 25, 2023, Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced the completion of a $48 million financing. The round includes existing investors F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management, as well as new investor Labcorp. Wilson Sonsini Goodrich & Rosati advised Adela on patent matters related to the transaction.